InsidersTradesSigma
Track the Immunome, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €3.1bn. The latest transaction was reported on 6 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ABHMC II, LLC. Every trade is accessible without an account.
Analysts rate Immunome, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$36.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Immunome, Inc. is a biopharmaceutical company focused on developing antibody-based therapies for cancer and other diseases. It utilizes its antibody discovery platform to identify innovative therapeutic candidates.